Asklepios BioPharmaceutical
Asklepios BioPharmaceutical, a subsidiary of Bayer AG, specializes in AAV gene therapy technology, focusing on treatments for various medical conditions including congestive heart failure, for which its AB-1002 program has received FDA Fast Track Designation.
Company Overview
Asklepios BioPharmaceutical, founded in 2001, specializes in AAV gene therapy technology and therapeutics. The company is headquartered in Research Triangle Park, North Carolina, and operates as a wholly owned and independently operated subsidiary of Bayer AG. Additional facilities are located in Philadelphia, Pennsylvania; Upper Arlington, Ohio; Edinburgh, Scotland; Heidelberg, Germany; and Paris, France, with manufacturing facilities in San Sebastian, Spain.
Gene Therapy Technology
Asklepios BioPharmaceutical focuses on developing AAV gene therapy technology. Their clinical pipeline includes therapies aimed at neuromuscular, metabolic, cardiovascular, and central nervous system conditions. The company has received FDA Fast Track Designation for its AB-1002 investigational gene therapy program in treating congestive heart failure.
Partnerships and Licensing
Asklepios BioPharmaceutical's technology and AAV therapeutic assets have been acquired or licensed by major pharmaceutical companies, including Bayer, Pfizer, Takeda, and Novartis. These collaborations enhance the company's reach in the gene therapy field.
Patent Portfolio
The company holds a robust portfolio of over 800 patents and patent applications related to gene therapy development, clinical processes, and manufacturing. This extensive intellectual property portfolio signifies Asklepios BioPharmaceutical's strong foothold in the gene therapy industry.
Global Operations
Asklepios BioPharmaceutical operates globally with facilities in several countries. They have research and development centers in North Carolina, Pennsylvania, Ohio, Scotland, Germany, and France, and manufacturing facilities in Spain. This international presence supports their extensive work in gene therapy development.